MedTrace Logo

EMD 121974 in Treating Patients With Progressive or Recurrent Glioma

NCT00006093 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-24

No results posted yet for this study

Summary

RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor.

PURPOSE: Phase I/II trial to study the effectiveness of EMD 121974 in treating patients who have progressive or recurrent malignant glioma.

Conditions

Interventions

DRUG

cilengitide

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • New Approaches to Brain Tumor Therapy Consortium

    lead OTHER

Principal Investigators

  • Louis B. Nabors, MD · University of Alabama at Birmingham

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30
Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006093 on ClinicalTrials.gov